POLE and neoplasm: A number of prognostic markers like histological assessment of tumour type and grade, hormone receptor status, PTEN expression, mismatch repair proteins (MLH1, PMS2, MSH2, MSH6), POLE exon 3 mutation, CTTNB1 mutation, L1CAM overexpression, and TP53 aberrations allow stratification of patients according to their risk of recurrence (9–20).